SLC5A2 and type 2 diabetes mellitus: The recently studied sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and dapagliflozin in EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and DECLARE–TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trials, respectively, reduced the rate of cardiovascular death of diabetic patients compared with placebo (21, 22).